David Bassett is a partner in the firm's Litigation/Controversy Department, a member of the Intellectual Property Litigation Practice Group and FinTech Group. He is the former chair of the firm's Associates Committee and of the firm's Intellectual Property Practice. He joined the firm in 1989.
Mr. Bassett's practice concentrates on intellectual property litigation, particularly on biotechnology, pharmaceutical and Hatch-Waxman patent disputes. He also represents clients in a wide variety of other business disputes, including breach of contract, Lanham Act and Internet-related claims. Mr. Bassett's intellectual property litigation clients have included Forest (Allergan), Gilead Sciences, Foundation Medicine, Precision BioSciences, Biogen, Procter & Gamble, Calgene, Cephalon, Kurzweil Music, RSA Security, Braintree Laboratories and many others. His practice has covered all facets of litigation, including discovery, settlement, alternative dispute resolution, trials and appeals. Mr. Bassett has been lead trial lawyer in more than a dozen patent trials (both bench and jury), and has appeared before the Courts of Appeals for the First and Federal Circuits.